Liraglutide and Insulin Real-World Use Evaluated for Quality of Life and Costs in Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) management often involves a range of therapies, including Liraglutide, a GLP-1R agonist, and various insulin regimens. While clinical trials establish efficacy and safety, understanding the real-world impact on patient quality of life and healthcare costs remains a critical gap. This health service research aims to bridge this by collecting data from daily clinical practice, providing insights into the comparative economic and humanistic burden associated with these common T2DM treatments. This perspective is vital for optimizing long-term patient care and resource allocation.

This health service research study, conducted in Europe, collects real-world data from daily routine clinical practice. It observes patients with Type 2 Diabetes Mellitus receiving either Liraglutide or insulin as standard care. The primary objective is to evaluate patient quality of life and disease costs associated with these treatments. This observational design aims to capture actual treatment patterns and patient experiences beyond controlled trial settings.